Table 4. Correlation between clinico-pathological variables and LVI and BVI.
|
LVI
|
BVI
|
|||||
|---|---|---|---|---|---|---|
| Pos | Neg | Pos | Neg | |||
| T status | ||||||
| T1 | 39 | 24 | P*=0.03 | 17 | 46 | P*=0.001 |
| T2 | 23 | 4 | 17 | 10 | ||
| T3 | 2 | 1 | 1 | 2 | ||
| T4 | 2 | 0 | 1 | 1 | ||
| N status | ||||||
| N0 | 33 | 19 | P=0.05 | 16 | 36 | P=0.14 |
| N1 | 18 | 9 | 11 | 16 | ||
| N2 | 10 | 0 | 5 | 5 | ||
| N3 | 5 | 0 | 4 | 1 | ||
| Histological type | ||||||
| IDA | 55 | 17 | P=0.009 | 32 | 40 | P=0.07 |
| ILA | 3 | 7 | 2 | 8 | ||
| Special Type | 8 | 5 | 2 | 11 | ||
| Tumour grade | ||||||
| 1 | 15 | 16 | P=0.005 | 4 | 27 | P<0.001 |
| 2 | 26 | 9 | 12 | 23 | ||
| 3 | 25 | 4 | 20 | 9 | ||
| ER | ||||||
| Pos | 47 | 23 | P=0.41 | 25 | 45 | P=0.46 |
| Neg | 19 | 6 | 11 | 14 | ||
| PR | ||||||
| Pos | 42 | 21 | P=0.41 | 21 | 42 | P=0.20 |
| Neg | 24 | 8 | 15 | 17 | ||
| p53 | ||||||
| Pos | 18 | 4 | P=0.15 | 10 | 12 | P=0.40 |
| Neg | 48 | 25 | 26 | 47 | ||
| HER2/neu | ||||||
| Pos | 3 | 1 | P=1.00 | 3 | 1 | P=0.15 |
| Neg | 63 | 28 | 33 | 58 | ||
| Fibrotic focus | ||||||
| Absent | 33 | 23 | P=0.02 | 15 | 41 | P=0.005 |
| <1/3th tumour diameter | 18 | 2 | 8 | 12 | ||
| >1/3th tumour diameter | 15 | 4 | 13 | 6 | ||
| Growth pattern | ||||||
| Infiltrative | 9 | 6 | P=0.66 | 2 | 13 | P=0.09 |
| Mixed | 48 | 20 | 28 | 40 | ||
| Expansive | 9 | 3 | 6 | 6 | ||
BVI=blood vessel invasion; ER=oestrogen receptor; LVI=lymph vessel invasion; N=nodal; Neg=negative; Pos=positive; PR=progesterone receptor; T=tumoural.
P*: P-value of a 2 × 2 table only including T1 and T2 tumours.